共 50 条
- [31] FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASESCANCER RESEARCH, 2024, 84 (09)Bartsch, RupertBerghoff, Anna SophieFurtner, JuliaMarhold, MaximilianBergen, Elisabeth SophieRoider-Schur, SophieStarzer, Angelika MariaMair, MaximilianForstner, HeidrunRottenmanner, BeateAretin, Marie-BernadetteDieckmann, KarinBago-Horvath, ZsuzsannaHaslacher, HelmuthWidhalm, GeorgIlhan-Mutlu, AysegulMinichsdorfer, ChristophFuereder, ThorstenSzekeres, ThomasOehler, LeopoldGruenberger, BirgitPfeiler, GeorgSinger, Christian F.Weltermann, AnsgarBerchtold, LuziaPreusser, Matthias
- [32] Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesNEURO-ONCOLOGY, 2024,Bartsch, RupertBerghoff, Anna SophieFurtner, JuliaMarhold, MaximilianBergen, Elisabeth SophieRoider-Schur, SophieMair, Maximilian JohannesStarzer, Angelika MartinaForstner, HeidrunRottenmanner, BeateAretin, Marie-BernadetteDieckmann, KarinBago-Horvath, ZsuzsannaHaslacher, HelmuthWidhalm, GeorgIlhan-Mutlu, AyseguelMinichsdorfer, ChristophFuereder, ThorstenSzekeres, ThomasOehler, LeopoldGruenberger, BirgitPfeiler, GeorgSinger, ChristianWeltermann, AnsgarBerchtold, LuziaPreusser, Matthias
- [33] Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3CANCER RESEARCH, 2015, 75Cortes, JavierDieras, VeroniqueRo, JungsilBarriere, JeromeBachelot, ThomasHurvitz, SaraLe Rhun, EmilieEspie, MarcKim, Sung-BaeSchneeweiss, AndreasSohn, Joo HyukNabholtz, Jean-MarcKellokumpu-Lehtinen, Pirkko-LiisaTaguchi, JuliePiacentini, FedericoCiruelos, EvaBono, PetriOuld-Kaci, MahmoudRoux, FlavienJoensuu, Heikki
- [34] Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): Results from a phase II prospective trial.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Rouzier, R.Lambaudie, E.Pierga, J.Petit, T.Delozier, T.Ferrero, J.Campone, M.Gligorov, J.Lerebours, F.Roche, H.Pau, D.Viens, P.Salmon, R. J.
- [35] Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRAANNALS OF ONCOLOGY, 2014, 25 (06) : 1116 - 1121Swain, S. M.Baselga, J.Miles, D.Im, Y. -H.Quah, C.Lee, L. F.Cortes, J.
- [36] Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10Hurvitz, SaraSingh, RashiAdams, BradTaguchi, Julie A.Chan, DavidDichmann, Robert A.Castrellon, AurelioHu, EddieBerkowitz, JonathanMani, ArunaDiCarlo, BrianCallahan, RenaSmalberg, IraWang, XiaoyanMeglar, IvanaMartinez, DiegoHobbs, EvthokiaSlamon, Dennis J.
- [37] Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial)JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Guarneri, V.Frassoldati, A.Bottini, A.Generali, D. G.Cagossi, K.Artioli, F.Bisagni, G.Boni, C.Ravaioli, A.Amadori, D.Musolino, A.Cavanna, L.Untch, M.Orlando, L.Giardina, G.Piacentini, F.Tagliafico, E.Bagnalasta, M.D'Amico, R.Conte, P. F.
- [38] Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 TrialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 198 - +Rugo, Hope S.Im, Seock-AhCardoso, FatimaCortes, JavierCurigliano, GiuseppeMusolino, AntoninoPegram, Mark D.Bachelot, ThomasWright, Gail S.Saura, CristinaEscriva-de-Romani, SantiagoDe Laurentiis, MichelinoSchwartz, Gary N.Pluard, Timothy J.Ricci, FrancescoGwin II, William R.Levy, ChristelleBrown-Glaberman, UrsaFerrero, Jean-Marcde Boer, MaaikeKim, Sung-BaePetrakova, KatarinaYardley, Denise A.Freedman, OritJakobsen, Erik H.Gal-Yam, Einav NiliYerushalmi, RinatFasching, Peter A.Kaufman, Peter A.Ashley, Emily J.Perez-Olle, RaulHong, ShengyanRosales, Minori KoshijiGradishar, William J.
- [39] Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label randomized, multicenter, phase IIIB ESCAPE trialCANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40Kaidarova, DilyaraZhavrid, EdvardShatkovskaya, OxanaProkharau, AliaksandrAkhmed, NinaSembayev, DaurenRutzhanova, ZhannaIvankov, Alexandr
- [40] Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)CANCER RESEARCH, 2012, 72Fernandez, M.Calvo, I.Martinez, N.Herrero, M.Quijano, Y.Duran, H.Garcia-Aranda, M.Suarez, A.-Rios, F. LopezPerez, D.Perea, S.Hidalgo, M.Garcia-Estevez, L.